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Abstract
Genome-wide association analysis in populations of European descent has recently found more than a hundred genetic
variants affecting risk for common disease. An open question, however, is how relevant the variants discovered in
Europeans are to other populations. To address this problem for cardiovascular phenotypes, we studied a cohort of 4,464
African Americans from the Jackson Heart Study (JHS), in whom we genotyped both a panel of 12 recently discovered
genetic variants known to predict lipid profile levels in Europeans and a panel of up to 1,447 ancestry informative markers
allowing us to determine the African ancestry proportion of each individual at each position in the genome. Focusing on
lipid profiles—HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), and triglycerides (TG)—we identified the lipoprotein lipase
(LPL) locus as harboring variants that account for interethnic variation in HDL-C and TG. In particular, we identified a novel
common variant within LPL that is strongly associated with TG (p= 2.761026) and explains nearly 1% of the variability in this
phenotype, the most of any variant in African Americans to date. Strikingly, the extensively studied ‘‘gain-of-function’’ S447X
mutation at LPL, which has been hypothesized to be the major determinant of the LPL-TG genetic association and is in trials
for human gene therapy, has a significantly diminished strength of biological effect when it is found on a background of
African rather than European ancestry. These results suggest that there are other, yet undiscovered variants at the locus that
are truly causal (and are in linkage disequilibrium with S447X) or that work synergistically with S447X to modulate TG levels.
Finally, we find systematically lower effect sizes for the 12 risk variants discovered in European populations on the African
local ancestry background in JHS, highlighting the need for caution in the use of genetic variants for risk assessment across
different populations.
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Introduction
A main motivation for genome-wide association studies
(GWAS) of disease phenotypes has been the promise of identifying
markers of disease risk, which may augment the prognostic value
of conventional clinical measures [1,2]. Although many such
variants have been identified, the corresponding studies have been
based almost entirely in populations of European descent. Thus, it
remains to be seen if these markers will have prognostic utility in
admixed individuals, such as African or Hispanic Americans, in
whom each chromosome is likely to be a mosaic of blocks of DNA
from different ancestral populations. African Americans, for
example, carry chromosomal segments that are derived predom-
inantly from West African and European American ancestral
populations. These two populations have been subject to differing
demographic history, which has led to differences in allelic
frequencies and patterns of linkage disequilibrium across the
genome [3,4].
We have previously used a form of whole-genome scanning
known as admixture mapping to search for genetic variants that
differ markedly in frequency between continental populations and
that also contribute to disease risk [5–9]. In persons of recently
mixed ancestry, each region of the genome is mapped according to
ancestral origin using a panel of markers that are highly
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differentiated in frequency between West Africans and European
Americans. The resulting maps are then analyzed to identify
genomic regions where individuals with disease have a marked
deviation in the proportion of one of the parental ancestries from
the genome–wide average [10–13]. Such regions in principle
should contain disease variants.
In the current work, we have investigated to what extent the
local ancestry information used in admixture mapping can inform
genetic association analysis in African Americans. We chose lipid
and cholesterol levels as our phenotypes of interest for several
reasons: 1) they represent the major modifiable risk factors for
coronary heart disease; 2) several GWAS of lipid profiles have
been conducted recently in populations of European descent,
yielding multiple potential risk variants [14–18]; and 3) the
lipoprotein profiles of African Americans and European Ameri-
cans differ, beginning in childhood [19] and persisting into
adulthood [20], with African Americans having lower levels of
triglycerides and very low density lipoprotein cholesterol, and
higher levels of HDL-C and apolipoprotein A-I. We have
incorporated local ancestry estimates into genetic association
analysis of cholesterol and TG phenotypes in the Jackson Heart
Study (JHS) [21]. We show, herein, how using such an analytic
approach in admixed populations can inform an understanding of
the genetic determinants of complex disease.
Results
We studied a data set of 4605 individuals from the JHS who
were consented for genotype analysis. The JHS is a long term,
community-based observational study that was developed as an
extension of the Jackson, MS cohort of the Atherosclerosis Risk in
Communities (ARIC) study, with the support of the National
Heart, Lung, and Blood Institute (NHLBI) [21]. It is designed to
investigate the factors that contribute to the very high prevalence
of common complex diseases among African Americans in
Mississippi, including hypertension, diabetes mellitus, myocardial
infarction, congestive heart failure, LVH, stroke, peripheral
vascular disease, and chronic renal disease. Hypercholesterolemia
is particularly prevalent in this population, with rates exceeding
35% for individuals above the age of 50 [22]. Of the 4605
individuals, 1448 are part of a family study and therefore include
relatives within the study. We were able to genotype successfully
4464 individuals using one of two panels of .1400 markers
selected for high differences in frequency between European
Americans and West Africans [7]. Demographic characteristics
are shown in Table 1.
African Ancestry Is Significantly Associated with
Triglyceride and HDL-Cholesterol Levels and Weakly
Associated with LDL-Cholesterol Levels
Using the ANCESTRYMAP software [10], we can make precise
estimates of individual ancestry in admixed individuals, which can be
correlated with continuous and dichotomous phenotypes (see
Methods). In the 4464 genotyped JHS participants, we found a
Author Summary
Single-base changes in DNA can affect biochemical
measures, such as blood cholesterol or lipid levels. Such
changes or ‘‘variants’’ can be associated with a trait either
because they cause the trait or because they are linked to
other causal variants. In either case, the associated
variant(s) may be useful in predicting the trait. The
chromosomes in which DNA is packaged cross over and
recombine with each other in each generation, so that in
historically separate populations, such as Africans and
Europeans, the patterns of genetic linkage between
variants differ. In the current study, we analyzed a large
group of African Americans, testing genetic variants that
had been associated with cholesterol and lipid levels in
European-derived populations to assess their predictive
value on two different genetic backgrounds within the
same cohort. The ability of some variants to predict
cholesterol or lipid traits was strongly dependent on
genetic background, indicating that they may be tightly
linked to other causal variant(s) in European populations
and may not, themselves, be directly responsible for trait
variability. We conclude that the predictive value of
specific variants for risk assessment can differ critically
across populations.
Table 1. Demographic Characteristics for the Genotyped Jackson Heart Study Participants.
All Unrelated
Unrelated with only African
local ancestry at LPL
Unrelated with European
local ancestry at LPL
Number 4464 3300 1887 728
Male (%) 36.8 37.8 37.4 37.4
Age (mean - years, 6std.) 55613 56611 57612 57612
BMI (mean - kg/m2 6std.) 3267 3267 3267 3267
Type II DM (%) 18.9 20.4 20.6 19.6
Cholesterol or TG-Lowering Medication (%) 12.5 13.6 13.8 13.7
LDL-Cholesterol: unmedicated | medicated
participants (mg/dL)
127636 | 113633 128637 | 113633 126636 | 112635 131637 | 119633
HDL-Cholesterol: unmedicated | medicated
participants (mg/dL)
51614 | 51614 52615 | 52614 52615 | 52615 51615 | 49615
Serum Triglycerides: unmedicated | medicated
participants (mg/dL)
106681 | 1296151 107683 | 1306164 106695 | 120678 110668 | 1566281
Overall African Ancestry (%) 8369 8269 8567 7667
Characteristics are shown for the 4464 genotyped participants, the 3300 unrelated individuals, the 1887 unrelated individuals with homozygous African local ancestry at
the LPL locus, and the 728 individuals with at least one ancestral European allele at LPL.
doi:10.1371/journal.pgen.1000342.t001
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mean African ancestry of 8369% (Table 1). We assessed the
association of overall ancestry (hereafter called global ancestry, in
contrast to local ancestry of a chromosomal segment) with each of
our three traits by linear regression (see Methods). Analysis was
limited to unrelated individuals, with one individual selected
randomly from each family, to avoid correlations arising from
relatedness. One hundred separate lists of unrelated individuals were
generated by repeated random sampling. We also performed logistic
regression, comparing the top and bottom quintile of the lipid
distributions, to see if there were differences in ancestry for extremes
of the population.
After adjusting for common covariates, which accounted for
10% of the TG variance, increased African ancestry was
significantly associated with decreased triglyceride levels (Table 2)
in both linear (p = 6.561025) and logistic regression analysis
(p = 0.0046). For every 10% decrease in African Ancestry, there is
a 3.960.9% increase in triglyceride level.
As shown in Table 2, HDL-C is also significantly associated
with African ancestry in both linear (p = 0.0009) and logistic
(p = 0.017) regression analysis (0.74 mg/dl HDL-C decrease per
10% decrease in African ancestry). For LDL-C, we included
individuals who were not on cholesterol-lowering medications
(n = 3521). LDL-C shows a significant association only in a
comparison of upper and lower quintiles (p = 0.027). Decreased
LDL-C levels were associated with increased African ancestry.
Our observed association of increased African ancestry with
increased HDL-C and decreased serum triglycerides and LDL-C
is in keeping with that seen in other cohorts [23,24], although we
were better able to quantify these relationships given the large size
of the study population and greater informativeness of the marker
panel. These findings support the hypothesis that some of the
population variation in lipid traits is indeed genetic, and can be
attributed to variants that have different frequencies in African
and European populations. Furthermore, this lipid profile of
elevated HDL-C, decreased triglycerides, and decreased LDL-C
would typically be considered protective towards atherosclerosis
and motivates a search for contributing genetic variants.
Whole-Genome Admixture Mapping Does Not Identify
Suggestive or Significant Loci for TG, HDL-C, or LDL-C
Levels
We conducted a genome-wide admixture scan by genotyping
our 4464 individuals with the markers informative for ancestry as
described above. We then used the ANCESTRYMAP software to
estimate the probability that each chromosomal segment in the
genome arose from either a European or African ancestor, and
evaluated the association of this ancestry estimate with TG/
cholesterol traits. The ANCESTRYMAP software is optimized for
dichotomous variables, so we defined cases and controls for each
of the three traits as the top and bottom quintiles. Thus in
distinction to the quantitative variable analysis shown above, we
have used a categorical variable for admixture mapping. Table S1
shows the results of the whole genome scan for all admixture runs.
Despite the promising association of global ancestry with TG,
HDL-C and LDL-C, we find no peaks meeting either our
suggestive or significant thresholds of association.
Exclusion of 96–100% of the Genome as Contributing
Substantially to Interethnic Variation in Lipid Profile Traits
To quantify the lack of association of lipid profile phenotypes
with ancestry, we constructed an exclusion map to rule out loci in
the genome as contributing substantially to ancestry-related risk of
being in the top or bottom quintile (categorical variable) for each
trait. For each position in the genome and for each trait we
estimated a credible interval for the factor by which the risk for the
phenotype due to African (or European) ancestry differs from that
due to the opposite ancestry. For all traits analyzed, and at a
significance of p,0.05, 96–100% of the genome could be
excluded as bearing risks .1.5-fold due to African or European
ancestry (Table S2), suggesting that no single gene makes such a
strong contribution to interethnic differences in TG and
cholesterol traits. We also constructed a more traditional exclusion
map, excluding markers for each trait for which the LOD score
was,22 (Figure S1) for a risk model of 1.5; this also excluded 82–
89% of the genome. However, our ability to exclude genetic
ancestry effects in the range of 1.2–1.5-fold risk, as seen for most
common disease variants identified to date [25], is much less (48–
59% of genome). Thus we sought other, integrative methods to
identify genetic determinants of interethnic variation.
Evaluation of Local Ancestry at Validated Genes that
Influence Lipid Levels Suggests Multiple Loci
Contributing to Population Differences in Lipid Profiles
Whole-genome scanning by admixture mapping and GWAS
has led to the identification of many new disease-associated gene
variants. However, the stringent criteria for declaring genome-
wide significance, resulting from the low prior probability of the
multiple hypotheses tested (.1000 in admixture mapping;
.100,000 in GWAS), have limited the number of peaks followed
up, and minimal overall heritability has been explained for most
complex traits. Many loci that do not meet genome-wide
significance might in fact be found to be associated with the trait
of interest if fine-mapping strategies were pursued. Prioritization of
such follow-up can be done by integrating data beyond the
genome scan itself, such as meta-analysis with other GWAS
[15,16], integration of linkage data with GWAS [26], or
prioritization using literature-based searches for candidates [9].
Five recent manuscripts [14–18] have identified and/or
validated 19 loci influencing TG, HDL-C and LDL-C levels in
whole genome association analyses. We determined local ancestry
at the most strongly associated SNP at each of these loci in our
cohort to see whether local European or African ancestry is
associated with variation in TG/cholesterol levels. A significant
association would not only suggest that the loci are important for
lipid variation in the JHS population, but that ethnic differences in
lipid profile could be attributable to frequency differences in the
associated risk alleles.
Table 2. Individual African-European Ancestry is associated
with Triglyceride and Cholesterol Levels.
p-value: Population-wide
p-value: Comparison of Upper
and Lower Quintiles of Trait
TG1 6.561025 0.0046
HDL-C2 0.00090 0.017
LDL-C3 0.40 0.027
1Adjusted for age, age2, gender, bmi, bmi2, type 2 diabetes (dm2), smoking.
2Adjusted for gender, bmi, bmi2, dm2.
3Adjusted for age, age2, gender, bmi, bmi2, dm2, smoking; individuals on
cholesterol-lowering medication were excluded.
Linear and logistic regressions were used to estimate the strength of
association of individual African/European ancestry with triglycerides and the
cholesterol traits.
doi:10.1371/journal.pgen.1000342.t002
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Table 3 shows p-values for the association of local ancestry with
the three lipid and cholesterol traits. Of the 27 associations tested,
ancestry was associated with TG, HDL-C or LDL-C at three loci
with p,0.05, including one at the p,0.005 level. Although none
of these associations would meet a p,0.05 significance threshold
with strict Bonferroni correction (0.0018 for 27 hypotheses tested),
we propose that for such strongly validated genes even a weakly
positive result may warrant further investigation.
Our local ancestry association analysis identified LPL (p= 0.01,
HDL-C), GCKR (p= 0.01, TG), and ApoB (p= 0.003, LDL-C) as
plausible genes for interethnic variation in lipid profile. Of these, LPL
also showed suggestive association with TG (p=0.14). Furthermore,
African Americans have been shown to have higher LPL activity
than European Americans, and in the same study, inclusion of LPL
activity in regression models rendered the association of ethnicity
with triglyceride levels non-significant [27]. We therefore decided to
pursue fine mapping of LPL to seek specific variants that contribute
to interethnic variation in TG and HDL-C levels.
Fine-Mapping of LPL Identifies Frequency-Differentiated
Variants for TG, HDL-C, and LDL-C
Using Tagger [28], we selected a dense panel of SNPs spanning
the LPL locus and extending 10 kB upstream of the transcriptional
start site and 15 kb downstream of rs10096633 (see below).
Tagging SNPs were selected at an r2 of 1.0 with MAF of $2% in
the Yoruba West African HapMap population (YRI). We then
forced these SNPs into Tagger to tag this region in CEU at an r2 of
1.0 with MAF of $5%. All lipid profile GWAS to date [14–18]
have found extremely strong association of TG with the well-
known rs328 SNP or a perfect proxy. We therefore included 2
perfect proxies for this SNP in CEU, rs325 and rs17482753,
yielding a total of 95 SNPs.
Both global and local ancestries can be significant confounders of
the association of a SNP with a phenotype in an admixed population,
such as African Americans. If a trait such as TG or HDL-C is
strongly associated with overall African or European ancestry, then
any SNP with frequency differentiation between Europeans and
Africans may appear falsely associated with the trait, a problem
known as population stratification. This confounding can be
corrected by including a term for global ancestry in the regression
model. Locally within the genome, however, strong admixture
linkage disequilibrium (i.e. blocks of shared ancestry) can extend over
many centimorgans. If the true risk variant differs in frequency
between European Americans and Africans, any SNP within the
block of admixture linkage disequilibrium (LD) may appear causally
related to the trait if it too is sufficiently differentiated in frequency to
be informative for local ancestry. This confounding occurs even after
correcting for global ancestry and is in fact the basis for admixture
mapping. Fortunately, it can also be addressed, by inclusion of a
term for local ancestry in the regression model. A final problem is
that for many genes, the pattern of LD varies depending on the
ancestral origin of the chromosomal segment. In general, blocks of
LD are much shorter in historically large populations such as
Africans than in historically smaller populations like Europeans.
Thus a SNP that is strongly associated with a trait of interest in one
population may show little or no association in another population
because of differing patterns of LD. This may help identify the actual
risk variant since, within an admixed population, a lone causal
variant would be expected to have a similar effect size on any local
ancestral background.
In our cohort, we calculated a linear regression residual for each
trait, where the regression model included the covariates described
above as well as global ancestry for each individual. This residual
was tested for association by stepwise regression with local
ancestry, the SNP genotype (in an additive model), and a term
for the SNP genotype-local ancestry interaction, computed as a
product of the local-ancestry term and SNP genotype (see
Methods). Statistical significance for genotype, and genotype-local
ancestry interaction were evaluated using ANOVA, with nested
regression models. As another approach to potential confounding
by differing LD patterns, we tested association of each SNP
separately in a subpopulation of 1860 individuals who had .95%
probability of two African ancestral chromosomes in the region
(JHS-AFR-2LPL), thus minimizing heterogeneity in local ancestry
background, and a subpopulation of 780 individuals with .95%
probability of at least one European ancestral allele (JHS-EUR-
1_2LPL, see Table 1 for demographic characteristics of these
subgroups). We also identified a small subgroup of 65 individuals
with .95% probability of two European ancestral alleles (JHS-
EUR-2LPL) for calculation of allele frequencies and linkage
disequilibrium parameters (Table 4, Table S3).
We successfully genotyped 85 of the 95 tagging SNPs. The
strength of the associations for each SNP with TG and HDL-C are
Table 3. Evaluation of the Association of Serum Lipid and
Cholesterol Levels with Local Ancestry at 19 Lipid Loci
Identified or Validated in Recent GWAS.
Trait Gene p-value
LDL APOB 0.0031
APOE 0.812
HMGCR 0.858
LDLR 0.843
MVK 0.826
NCAN 0.687
PCSK9 0.365
SORT1 0.475
TRIB1 0.224
HDL ABCA1 0.71
APOA5 0.37
CETP 0.65
GALNT2 0.47
LIPC 0.23
LIPG 0.11
LPL 0.012
MLXIPL 0.75
TRIB1 0.61
TG ANGPTL3 0.81
APOA5 0.86
APOB 0.07
GALNT2 0.37
GCKR 0.013
LPL 0.14
MLXIPL 0.19
NCAN 0.86
TRIB1 0.83
Local ancestry values were estimated using ANCESTRYMAP and the strength of
the association of local ancestry with each trait was evaluated by linear
regression as in Table 2. Associations significant at the p,0.05 level are shown
in bold.
doi:10.1371/journal.pgen.1000342.t003
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shown in Tables S4 and S5 with the top SNPs shown in Tables 4
and 5. In Table 4, three separate p-values per trait are shown for
each SNP, representing association across all 3300 individuals
(p_all), in the JHS-AFR-2LPL (p_afr), and for the significance of the
genotype-by-ancestry interaction term (p_trg_int). For triglycerides,
six of the 85 SNPs were associated at a significance level of p,0.0006
(Bonferroni correction for 85 hypotheses at p,0.05 significance
level), including rs328 and all 4 SNPs having r2 = 1 with rs328 in
JHS-EUR-1_2LPL: rs1011685 (p= 2.0610
25), rs325 (p=4.561025),
rs17482753 (p=4.961025), rs12679834 (p=2.761024). For these 5
SNPs pairwise r2 in JHS-AFR-2LPL ranges from 0.614-1 (Table S3).
The strongest association with TRG was in fact for rs10096633
(p=2.761026), where the risk allele for elevated triglycerides is
found at a frequency of 0.52 in YRI, and 0.87 in CEU (0.50 in JHS-
AFR-2LPL and 0.82 in JHS-EUR-2LPL; Table 4). rs10096633 is
strongly linked to rs328 in JHS-EUR-2LPL (r
2 = 0.79) but not so in
JHS-AFR-2LPL (r
2 = 0.059).
The rs328 variation leads to a premature stop codon, producing
a protein two amino acids short of a full-length product. It has
been presumed, based primarily on genetic association data and
physiologic studies of S447X carriers [29], that this S447X variant
represents a ‘‘gain-of-function’’ mutation with increased LPL
activity. Interestingly, the genotype-local ancestry interaction
terms were significant for rs328 (and rs325) (Table 4), indicating
a different strength of association on the African and European
local ancestry backgrounds. For the African American population
as a whole, the estimated effect size was 10.262.4% in TG level
per rs328 allele. Estimated effect sizes on the African and
European local ancestry backgrounds were obtained by repeating
the regression modeling using the JHS-AFRLPL and JHS-EURLPL
subpopulations. In this analysis, the effect size per rs328 allele was
4.563.4% on the African local ancestry background (Table 4,
p = 0.22) and 18.664.5% in the subgroup with one or more
European LPL chromosomes. The results are similar for the highly
correlated rs325, rs17482753, rs1011685 and rs12679834 SNPs,
with all showing a significant genotype-local ancestry interaction.
The significant dependence of effect size on local ancestral
background suggests that the effect seen in association studies in
European populations is not predominantly mediated by rs328,
but arises either from linkage of rs328 and other highly correlated
SNPs to some other causal variant, or from the aggregate effect of
multiple tightly linked causal variants. The effect size for
rs10096633 is more comparable in the three populations:
(6.261.2%, 4.561.6%, and 6.663.1% for total, JHS-AFR-2LPL,
and JHS-EUR-1_2LPL, respectively; Table 4). Although some
SNPs show a marked difference in effect size between local
ancestry backgrounds, the overall difference in genotype regres-
sion coefficients for the 85 SNPs in JHS-AFR-2LPL and JHS-EUR-
1_2LPL falls short of statistical significance (p = 0.07, Wilcoxon
signed-ranks test).
To determine if a multi-SNP model could better explain the
variability in TG levels, we performed stepwise linear regression
combined with ANOVA (see Methods) for the 100 sets of
unrelated JHS members to identify the top independent SNP
Table 4. Effect size of LPL variants on TG levels.
SNP Position f_afr f_eur f_all p_trg_all p_int_trg p_trg_afr effect_all6se effect_afr6se effect_eur6se
rs10096633 19875201 0.50 0.82 0.57 2.7E-06 0.15 7.1E-03 6.261.2 4.561.6 6.663.1
rs1011685 19875049 0.95 0.87 0.93 2.0E-05 0.027 0.25 11.562.5 4.463.6 21.564.5
rs325 19863608 0.94 0.86 0.93 4.5E-05 0.033 0.23 10.362.4 4.363.4 19.364.4
rs17482753 19876926 0.95 0.85 0.94 4.9E-05 0.023 0.33 10.862.5 3.763.6 21.464.5
rs328 19864004 0.94 0.86 0.93 7.1E-05 0.050 0.22 10.262.4 4.563.4 18.664.5
rs12679834 19864713 0.92 0.86 0.91 2.7E-04 0.013 0.33 8.362.1 3.163.0 17.864.3
rs327 19863816 0.55 0.68 0.59 7.8E-04 0.86 8.3E-03 4.361.2 4.461.6 3.762.8
rs1569209 19874450 1.00 0.90 0.98 9.9E-04 0.86 0.62 16.664.7 17.3632.5 18.965.6
rs13702 19868772 0.43 0.66 0.48 1.1E-03 0.81 0.042 4.161.2 3.461.6 2.262.8
rs3779788 19847373 0.98 0.91 0.95 1.2E-03 0.60 0.14 10.463.0 8.665.4 9.364.5
rs343 19855067 0.95 0.94 0.95 1.3E-03 0.27 0.16 9.262.7 5.763.8 12.965.3
rs1059611 19868843 0.79 0.83 0.81 2.1E-03 0.23 0.11 4.961.5 3.361.9 8.263.5
rs295 19860518 0.57 0.73 0.61 3.4E-03 0.61 8.8E-03 3.961.3 4.561.6 1.662.9
rs3916027 19869148 0.55 0.69 0.58 4.6E-03 0.77 0.025 3.661.2 3.861.6 2.262.8
rs264 19857460 0.87 0.87 0.86 5.3E-03 0.23 0.089 5.161.7 4.262.3 9.263.9
rs7000460 19848082 0.74 1.00 0.78 5.5E-03 0.69 0.051 4.461.5 3.761.8 0.1264.39
rs17091872 19876257 0.81 0.84 0.81 5.7E-03 0.27 0.25 4.461.5 2.462.0 4.663.5
rs15285 19868947 0.43 0.67 0.48 5.9E-03 0.70 0.047 3.561.2 3.361.6 0.3062.72
rs3289 19867472 0.92 1.00 0.92 8.1E-03 0.23 0.22 7.062.5 3.863.0 10.367.5
rs263 19857092 0.61 0.86 0.64 8.3E-03 0.092 0.12 3.561.3 2.661.7 5.663.1
rs2197089 19870653 0.15 0.41 0.21 9.3E-03 0.72 0.027 4.161.5 5.162.2 1.362.8
P-values for association of TRG with genotype in the total population (p_trg_all) and JHS-AFR-2LPL (p_trg_afr); SNPs with p,0.0006 are shown in bold. The p-value for
interaction (p_int_trg) is for the significance of the genotype6local ancestry term in the linear regression model for the total population (p,0.05 is shown in bold). The
percent change in TG level per LPL allele is shown with standard error for the total population (effect_all), JHS-AFR-2LPL (effect_afr) and JHS-EUR-1_2LPL (effect_eur). The
SNP frequencies in the total population (f_all), JHS-AFR-2LPL (f_afr) and JHS-EUR-2LPL (f_eur) are also shown, as well as the chromosomal position in bases on
chromosome 8.
doi:10.1371/journal.pgen.1000342.t004
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signals. The most frequently observed model included rs10096633,
rs1031045, rs3779788, rs11995036. A list of the top models is
shown in Table S6a.
Previous studies have established that LPL activity also
influences HDL-C levels, presumably by producing remnants of
triglyceride-rich lipoproteins, which can be used for HDL
assembly [30]. The LPL rs328 SNP and its proxies have also
been shown to be directly associated with HDL-C levels in
populations of European descent [14]. We therefore looked for
association of our fine-mapping LPL SNPs with HDL-C levels
(Table 5 for top SNPs, Table S5 for all SNPs) and found
association of one SNP with HDL-C at the p,0.0006 significance
level: rs13702 (r2 = 0.72 with rs10096633 in JHS-AFR-2LPL, and
allele frequency of 0.43 in JHS-AFR-2LPL). The top model of
independent signals for HDL-C is rs13702, rs3289, rs343,
rs10283151, rs2197089, rs6651471, rs9644636 (Table S6b).
The hypothesis of a differential effect size for rs328 on different
local ancestry backgrounds may be further evaluated using
individuals who are heterozygotes for both genotype and local
ancestry background. Presumably genotype heterozygotes might
show different TG levels depending on whether the allele for
higher TG resides on the African or European local ancestry
background at LPL. However, when we used ANCESTRYMAP
to output phased genotypes at rs328 (data not shown), the number
of individuals for whom we could generate confident estimates of
phase and local ancestry was insufficient for comparison.
In conclusion, using local ancestry estimates at the LPL locus to
minimize confounding by population stratification, we have
identified novel common variants within the LPL gene that are
moderately differentiated in frequency between African and
European Americans, and strongly associated with TG and
HDL-C levels. Furthermore, analysis of differential local ancestry
backgrounds suggests that the rs328 SNP explains at most a
modest amount of the TG variation at the LPL locus seen in
association studies in populations of European descent.
Genetic Association Analysis at Validated Lipid and
Cholesterol Loci Confirms the Importance of Local
Ancestry Estimates
To explore whether the use of local ancestry estimates informs
the analysis of other SNPs known to be strongly associated with
lipid and cholesterol traits, we genotyped 12 index SNPs (from 10
genes) that met genome-wide significance in recent lipid/
cholesterol GWAS. These have not yet been evaluated for
association in a large African-American population such as JHS.
Table 6 shows the overall p-value and a comparison of effect sizes
in the JHS-AFR-2 (n= 1727–1945, depending on the gene) and
JHS-EUR-1_2 (n = 540–728) subgroups at the locus of interest,
and the p-value for interaction of local ancestry with genotype. We
replicate the original association at p,0.05 for 7 of the 12 SNPs
(excluding rs328). The failure to replicate for the others may be a
consequence of reduced power due to sample size (the original
meta-analyses exceeded 8000 individuals) or a lower risk allele
frequency arising from genetic drift. There may also be
fundamental differences in effect size between European and
African Americans, reflecting unidentified gene6gene or gene
6environment interactions.
Just as with LPL, we can compare effect sizes in JHS-AFR with
JHS-EUR to look for any systematic variation with ancestral
background. Given that individuals in the cohort are likely to
share similar environments (independent of local ancestry at the
site of the tested variant), this type of internal comparison of effect
sizes is superior to comparing effects across different ethnic
Table 5. Effect size of LPL variants on HDL-C levels.
SNP Position f_afr f_eur f_overall p_hdl_all p_int_hdl effect_all6se effect_afr6se effect_eur6se
rs13702 19868772 0.43 0.66 0.48 1.2E-04 0.73 21.2860.33 21.6960.44 20.5960.69
rs328 19864004 0.94 0.86 0.93 6.7E-04 0.23 2.2460.64 1.5760.95 1.7961.10
rs15285 19868947 0.43 0.67 0.48 6.9E-04 0.44 1.1260.32 1.6260.44 0.1660.67
rs325 19863608 0.94 0.86 0.93 9.5E-04 0.17 22.1560.63 21.3860.93 22.1361.10
rs343 19855067 0.95 0.94 0.95 1.2E-03 0.85 22.4360.72 22.8061.05 21.7761.31
rs10096633 19875201 0.50 0.82 0.57 1.4E-03 0.71 1.1060.34 1.2060.44 0.6060.76
rs17482753 19876926 0.95 0.85 0.94 1.4E-03 0.23 2.1960.67 1.4560.99 1.9761.12
rs327 19863816 0.55 0.68 0.59 1.6E-03 0.52 21.0860.33 21.3060.45 21.0560.71
rs3289 19867472 0.92 1.00 0.92 2.0E-03 0.58 2.1260.67 2.6460.83 1.9261.79
rs2197089 19870653 0.15 0.41 0.21 2.1E-03 0.84 21.2960.41 21.9960.62 20.7360.71
rs1011685 19875049 0.95 0.87 0.93 2.4E-03 0.34 2.0760.66 1.4360.98 1.6861.10
rs3916027 19869148 0.55 0.69 0.58 3.4E-03 0.41 20.9960.33 21.1160.45 21.2060.68
rs12679834 19864713 0.92 0.86 0.91 3.7E-03 0.21 21.7360.58 21.1260.83 21.6361.07
rs10105606 19872128 0.26 0.66 0.34 4.5E-03 0.82 21.0360.36 21.4860.50 20.6660.70
rs331 19864685 0.56 0.68 0.60 6.1E-03 0.69 20.9260.32 21.1360.44 20.7160.70
rs1569209 19874450 1.00 0.90 0.98 7.7E-03 0.78 23.3861.24 27.6068.22 22.8061.38
rs295 19860518 0.57 0.73 0.61 8.3E-03 0.64 0.9260.34 1.1960.46 0.9260.72
rs301 19861214 0.66 0.74 0.68 8.8E-03 0.82 20.9460.35 21.2060.47 20.6160.73
P-values for association of HDL-C with genotype in the total population (p_hdl_all) and for the significance of the genotype6local ancestry term in the linear regression
model (p_int_hdl). SNPs with p,0.0006 are shown in bold. The change in HDL-C level (mg/dL) per LPL allele is shown with standard error for the total population
(effect_all), JHS-AFR-2LPL (effect_afr) and JHS-EUR-1_2LPL (effect_eur). The SNP frequencies in the total population (f_all), JHS-AFR-2LPL (f_afr) and JHS-EUR-2LPL (f_eur) are
also shown, as well as the chromosomal position in bases.
doi:10.1371/journal.pgen.1000342.t005
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populations, where multiple confounding factors may play a role.
We see that for 10 of the 12 index SNPs (excluding rs11591147,
which is fixed in YRI, but including rs328), the magnitude of the
effect is stronger in the European local ancestry subgroup than in
the African local ancestry subgroup, which is significant at
p = 0.034 by the Wilcoxon signed rank test (using standardized
residuals as the predicted variable). We note that some of the
differences are very small; nonetheless, this estimate is probably
conservative, as our JHS-EUR-1_2 subgroups include many
individuals with one allele of African local ancestry at LPL. The
systematic difference in effect size suggests that the majority of
these index SNPs are markers for the major causal SNP(s), with
weaker SNP-SNP correlations seen in the ancestral West African
population than in the ancestral European population, leading to
smaller effect sizes.
Some examples are illustrative. rs3135506, which encodes for a
S19W mutation in the endoplasmic reticulum signal peptide of
ApoA5 [31] is likely responsible for the majority of the effect seen in
association studies in both populations, given its similar effect sizes
in JHS-AFR-2 ApoA5 (11.960.9 mg/dL) and JHS-EUR-1_2 ApoA5
(14.867.0 mg/dL). Further, it is not likely that there are other
major causal variants linked to rs3135506 in one population but
not the other.
The intronic rs780094 variant in GCKR is significantly
associated with TG in JHS (p= 0.00038). The effect size in JHS-
AFRGCKR (5.561.1% per allele) is smaller than that seen in JHS-
EURGCKR (8.463.2% per allele), although the p-value for
interaction is not significant (p = 0.56). This observation can be
explained by considering LD patterns in the respective HapMap
populations with respect to the likely causal allele, rs1260326,
which encodes a leucine to proline change at amino acid 446 [16].
The r2 value of rs780094 with rs1260326 is 0.93 in CEU but only
0.42 in YRI. This modest difference can explain the similarly
modest difference in effect sizes between JHS-EUR-2GCKR and
JHS-AFR-2GCKR, although given our relatively small sample size,
we cannot exclude the contribution of chance variation.
Local ancestry analysis reveals a similar pattern for most of the
other SNPs tested, with significant overall association and with
effect size in JHS-EUR exceeding that in JHS-AFR. A more
marked variation in effect size with ancestry is seen for rs662799 in
ApoA5. This SNP, found in the 59 UTR of the ApoA5 gene, has a
strong association in Willer et al [16] with an estimated effect size
per allele of 16.9 mg/dl. An even stronger effect size is seen in
JHS-EURApoA5 (21.565.5% per allele) but the effect is negligible in
JHS-AFRApoA5 (1.161.0% per allele), leading to a significant p-
value for interaction (p= 0.03). rs662799 and rs328 (LPL) are thus
the two SNPs that show a sufficiently marked difference in effect
sizes between local ancestry subgroups to have a significant
interaction effect.
Discussion
We have demonstrated that local ancestry-based analysis in
admixed populations such as African Americans adds novel
insights beyond studies of genetic determinants of disease
performed in populations of European descent. We used precise
individual ancestry estimates to show a highly significant
association of individual African/European ancestry with serum
TG and HDL-C, suggesting strongly that genetic factors account
for at least some of the epidemiologically observed interethnic
differences. However, using local ancestry estimates in the context
of whole-genome admixture mapping for TG, HDL-C, and LDL-
C, we did not identify any genes with strong contributions to these
trends. Thus, although it is likely that there are genetic variants
whose frequency differences contribute to interethnic variability in
lipid profile, these appear to have relatively modest effects. This is
in keeping with our prior work on hypertension [9], and with the
generally modest effects of lipid profile variants seen in recent
GWAS/meta-analysis studies [14–18].
Analysis of the association of local ancestry with TG/HDL-C/
LDL-C at validated lipid profile loci led to prioritization of LPL for
fine-mapping. Overall, we identified rs10096633 as a credible
candidate for variation in TG levels, and rs13702 as a candidate
for variation in HDL-C. Remarkably, analysis within the
homozygote African local ancestry background showed that the
extensively studied rs328 variant, which encodes a premature stop
Table 6. Comparison of association of validated SNPs with lipid and cholesterol phenotypes in JHS, JHS-AFR-2LPL and JHS-EUR-
2LPL.
Trait Gene SNP Type p_all p_all_int effect_all6se effect_afr6se effect_eur6se f_afr f_eur f_all
HDL-C LIPC rs1800588 Upstream 0.10 0.53 0.5660.34 0.5560.34 1.360.8 0.50 0.58 0.50
HDL-C LIPG rs2156552 Intergenic 0.011 0.84 22.560.9 23.562.2 22.361.3 0.97 0.91 0.97
HDL-C CETP rs3764261 Downstream 2.7E-09 0.86 22.160.3 22.060.3 22.160.8 0.67 0.67 0.67
HDL-C ABCA1 rs3890182 Intronic 0.14 0.06 0.7560.50 0.8560.51 21.261.1 0.88 0.86 0.88
HDL-C LIPC rs4775041 Intergenic 7.2E-03 0.21 21.460.5 21.160.5 21.760.9 0.88 0.90 0.88
LDL-C PCSK9 rs11591147 Coding (Non-Syn) 1.2E-03 0.12 231.469.6 NA 224.9612.1 1.00 1.00 1.00
LDL-C HMGCR rs12654264 Intronic 0.085 0.54 1.961.1 1.461.2 3.462.2 0.68 0.68 0.68
LDL-C LDLR rs6511720 Intronic 1.4E-06 0.79 27.061.4 27.061.5 27.163.1 0.86 0.87 0.86
LDL-C ApoB rs693 Coding (Syn) 0.21 0.17 21.661.3 20.7861.58 23.762.3 0.79 0.67 0.78
TG ApoA5 rs3135506 Coding (Non-Syn) 1.6E-06 0.39 13.662.6 11.960.9 14.867.0 0.95 0.98 0.94
TG ApoA5 rs662799 59-UTR 0.069 0.03 3.561.9 1.161.0 21.565.5 0.88 0.86 0.88
TG GCKR rs780094 Intronic 3.8E-04 0.56 6.461.7 5.561.1 8.463.2 0.83 0.82 0.82
TG LPL rs328 Nonsense 7.1E-05 0.05 10.262.4 4.563.4 18.664.5 0.94 0.86 0.93
P-values for association of TG, LDL-C or HDL-C with genotype in the total population (p_all) and p-value for interaction (p_all_int) are shown (p#0.05 is shown in bold).
The percent change in TG or change in HDL-C or LDL-C level (mg/dL) per allele is shown with standard error for the total population (effect_all), JHS-AFR-2LPL (effect_afr)
and JHS-EUR-1_2LPL (effect_eur). The SNP frequencies in the total population (f_all), JHS-AFR-2LPL (f_afr) and JHS-EUR-2LPL (f_eur) are also shown.
doi:10.1371/journal.pgen.1000342.t006
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codon in LPL, is directly responsible for at most a modest amount
of variation in TG levels.
The S447X premature stop codon, caused by the rs328 variant
in LPL, has a contentious history as a putative gain-of-function
mutation, with considerable debate as to whether it demonstrates
increased lipolytic activity [29,32]. Interestingly, it has also been
associated with a reduced risk of cardiovascular disease, including
myocardial infarction [33]. Largely on the basis of the observed
beneficial associations of the S447X variant in population studies,
therapeutic trials with viral delivery of the S447X LPL transgene
have been conducted in animal models [34,35], and safety trials in
lipoprotein lipase-deficient patients have also begun [36]. Our
findings suggest that the S447X variant may not be the major
causal SNP within LPL that influences TG levels, and that it is
primarily a marker for the causal variant(s) in European-derived
populations. This finding—taking advantage of the unique short
range linkage disequilibrium in chromosomes of African ances-
try—emphasizes the challenges of assigning causality based on
genetic association, and is cautionary for the marketing of genetic
marker-based tests for disease risk assessment. When these tests are
based on any variant other than the causal allele, utility may not
extend to ethnic groups differing from the original study
population. Prognostication in African Americans based on a
SNP such as rs328 would require knowledge of LPL local ancestry
for each individual while, for a SNP like rs10096633, with more
uniform effect size, this information would not be required.
Although SNPs with much weaker effects on one ancestral
background may just be non-functional markers, situations could
also exist where they could be causal but still have differential effects.
The most plausible scenario might be that multiple functional
variants comprise a single haplotype more frequently in one
subpopulation than in the other. This might be the case more often
in European populations (and on local European ancestral
background in admixed populations), where LD extends over longer
distances, resulting in systematically lower effect sizes on African
local ancestry backgrounds for SNPs identified in GWAS studies of
European-derived populations. Even in the case where there is only
a single causal variant being tested, gene-gene epistatic effects from
variants at other loci that are at different frequencies in the two
subpopulations could influence effect size. Finally, environmental
influences on effect size may also differ by ancestral background.
In JHS-EUR-1LPL (19% of our population), the effect sizes for
rs328 (minor allele frequency of 12.5% in CEU) and closely
correlated SNPs are large, ranging from 18–22% of variation in
TG levels per risk allele, and accounting for almost 4% of the
residual trait variance. This effect is comparable to or exceeds the
effect of rs328 (or its proxies) in populations of European descent,
which has been estimated at 14 mg/dL [16] or 13.8% [17] per
allele. The strongest effect size for LPL variants in JHS-AFR-2LPL
is less, at 6% (for rs10096633 and rs13702). Since we tagged the
LPL gene densely this raises the question of why we failed to find a
variant with a large effect size on this African local ancestry
background. Possible explanations include that the rs328 variant is
in LD with multiple variants affecting TG levels in the European
local ancestry background, that epistatic effects of other frequency-
differentiated SNPs interact with that of rs328, that the true risk
variant(s) may lie outside our tagging boundaries, or that a strong
risk allele in LD with rs328 in Europeans is at very low frequency
in the West African population.
We extended our local ancestry based association analysis to
previously validated TG/cholesterol loci, and found replication for
7 of 12 loci at p,0.05. However, we observed an overall trend of
weaker effect size in JHS-AFR than JHS-EUR, with some marked
differences such as rs662799 in ApoA5, suggesting that many of
these ‘‘index’’ SNPs are merely tagging causal alleles, with the
effect size depending on the correlation between the index SNP
and the causal SNP(s). Again, this has clear implications for the use
of SNPs identified in one ethnic population as markers of disease
risk in other groups with differing demographic history.
In conclusion, we have developed a local-ancestry based
approach to genetic association analysis in admixed populations,
and using it, we have identified several variants in the LPL gene
that contribute to African/European American differences in lipid
profiles. The differing patterns of linkage disequilibrium on
different local ancestry backgrounds have allowed us to explore
plausibility of causality for established variants. We have also laid
the foundation for future studies to identify variants that would be
suitable as risk markers in African American populations. Finally,
our work highlights some of the challenges and opportunities that
derive from extending the results of genetic association analyses
across ethnic groups, and admixed groups in particular.
Materials and Methods
Statistical Analysis
Linear and logistic regression analyses were used to evaluate
association of global ancestry with lipid and cholesterol pheno-
types. For linear regression, individuals were ranked in terms of
increasing quantitative trait, and the top and bottom 0.5% of
individuals were eliminated from further analysis as these extreme
phenotypes are thought to be more likely attributable to
monogenic disorders. For the LDL-C analyses, all individuals on
cholesterol-lowering medication were also eliminated, as this trait
is particularly sensitive to therapy. For the logistic regression
analysis, ‘‘cases’’ and ‘‘controls’’ were selected as the top and
bottom quintile of the distribution for each trait. A logistic
regression model was then developed to predict case or control
status for each trait including age, age2, BMI, BMI2, gender, type
2 diabetes mellitus and smoking status as possible covariates, with
covariates selected for the model by stepwise forward regression.
The significance of association of case/control status and global
African/European ancestry was assessed using nested logistic
regression models and the likelihood ratio test [37].
We randomly selected only one member of each family to be
included in all genotypic analyses. To minimize bias, we generated
100 overlapping sets of 3300 unrelated individuals and conducted
all statistical analyses on each set, averaging the results.
For linear regression, triglyceride values were log transformed.
The individual’s multivariable-adjusted lipid residual was used as
the phenotype in phenotype association analyses with global
ancestry, local ancestry, and genotype. For genotype-phenotype
association analyses, we assumed an additive model of inheritance
and tested for the strength of association by ANOVA [38] with
nested linear regression models, which included local ancestry,
local ancestry+genotype, and local ancestry+genotype+genotype6
local ancestry interaction. The genotype-local ancestry interaction
term was computed as a product of the local-ancestry term and
SNP genotype, and is a continuous variable ranging from of 0 to 2.
We also conducted separate linear regression in a subset of 1860
individuals with a .95% probability of two African ancestry
alleles at the LPL locus and in a subset of 728 individuals with a
high (.95%) probability of 1 or more European ancestral alleles
(local ancestry .48% European ancestry). For the subset of
individuals with homozygous African local ancestry, we tested the
association of the multivariable-adjusted lipid residual against the
SNP genotype in an additive model of inheritance. Effect sizes
were estimated by evaluating what effect a unit change in genotype
would have on the predicted value of the trait.
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Multi-SNP models were identified with stepwise linear regres-
sion and the anova function in R. For each of the 100 sets of 3300
individuals, the top SNP associated with the phenotype residual of
interest was identified and added to the regression model. The
remaining SNPs were then each tested by comparing the model
with and without the SNP by ANOVA and the most significant
SNP included if the p-value for comparing was ,0.05. This
process was continued for each of the 100 sets of individuals until
no additional SNP improved the model at the p,0.05 threshold.
For each SNP that retained significance after a Bonferroni
correction, we re-estimated local ancestry at LPL by forcing it into
the set of markers used to estimate local ancestry (see below), so
that the joint distribution of ancestry and genotype could be
appropriately tested for association.
Estimation of allele frequencies and r2 for SNPs was performed
using the R GeneticsBase package. All statistical analyses were
performed using R (2.7.0).
Selection of Case and Control Samples
The samples in this study (n = 4605) were all self-identified
African Americans in the Jackson Heart Study [21]. Between Sept.
2000 and March 2004, 5,302 African Americans were recruited
from three counties, Hinds, Rankin, and Madison, which comprise
the Jackson, MS metropolitan area. Unrelated JHS participants
were drawn from three sources in roughly equal numbers: (1)
former ARIC participants; (2) participants selected randomly from
a commercial residential listing; and (3) a constrained volunteer
sample for which demographic cells for recruitment were designed
to mirror the overall target population.
For each trait (TG, LDL-C, HDL-C), the linear regression
residual was calculated for each individual with either a minimally
adjusted model, using age, age2, and gender as possible covariates,
or a fully adjusted model with age, age2, BMI, BMI2, gender, type
2 diabetes mellitus and smoking status as possible covariates.
Individuals were ranked by regression residual, and the top and
bottom quintiles of individuals were selected to be cases and
controls respectively for the admixture scans.
For each trait and each regression model (3 traits62 regression
models), we selected only one member of each family to be
included in the admixture run. This was selected to be the
individual with either the highest regression residual for that run or
the lowest regression residual for that run. A separate run was
performed for each combination, leading to a total of 12
admixture scans (Table S1).
Admixture Mapping and Markov Chain Monte Carlo Data
Analysis for Inference of Ancestry and Testing of Disease
Association
The ANCESTRYMAP software[10] was used for all analyses.
The program generates local ancestry estimates by integrating
information from a panel of densely spaced markers differentiated
in frequency between African and European populations. The
4464 JHS individuals were genotyped on one of two panels of
markers informative for West African vs. European ancestry [8]:
976 were genotyped on an older ‘‘Phase 2’’ Panel of 1536 markers,
and 3488 were genotyped on an updated ‘‘Phase 3’’ Panel of 1536
markers. After quality checks, 1408 SNPs in the ‘‘Phase 2’’ Panel
and 1447 SNPs in the ‘‘Phase 3’’ Panel were used for subsequent
analyses. The LOD score for association, defined as the log ratio of
the likelihood of the data under a disease model divided by the
likelihood of the data under no disease model, was evaluated at
equally spaced points across the genome. At each of these points,
the disease likelihood was evaluated with a multiplicative risk
model, with risk of disease integrated over the inheritance of 0, 1,
and 2 copies of an African ancestral allele. Being based on
Bayesian statistics, the ANCESTRYMAP software requires
specification of a prior distribution of risk models; we used a
range of ten risk models from 1.5-fold increased risk due to
inheritance of one African ancestral allele to 1.5-fold increased risk
due to inheritance of one European allele, with cases, controls, or
both used in the analysis. For each point in the genome, we
averaged the Bayes factors generated for each risk model, with the
LOD score corresponding to the log-base-10 of this number.
Frequency Estimates from the Ancestral Populations
Frequency estimates for each of the SNPs in Africans and
Europeans, were obtained with previously published data [6,39]
and data from the International HapMap Project [40]. These
samples provided a Bayesian prior distribution for the parental
population allele frequencies as described in reference [10].
Construction of Exclusion Map
To obtain credible intervals for increased risk due to African
ancestry across the genome, we repeated the procedure described
in [9]. We ran ANCESTRYMAP repeatedly for 65 separate
disease risk models (0.40, 0.42, 0.44, 0.46 …, 1.66, 1.68 and 1.70-
fold increased risk due to one European allele), and searching for
the maximum likelihood risk model. We evaluated LOD scores at
equally spaced points across the genome, and for each point we
averaged the LOD scores for the four runs of each lipid or
cholesterol trait. The 95% credible intervals for increased risk due
to African (or European) ancestry were obtained by a likelihood
ratio test, with the interval including all risk models for which the
log-base-10 of the likelihood of the disease model was within 0.883
of the maximum. We also computed an exclusion map for each
trait for a 1.5-fold increased risk of Case status with inheritance of
one copy of the African (or European) local ancestral allele. We
evaluated the Cases-only LOD score at 3,622 equally spaced
points across the genome, and excluded points with LOD scores
,22. The percentage of points excluded was 84.2% (increased
risk due to African ancestry) and 88.5% (increased risk due to
European ancestry) for TG; 82.6% and 91.6% for HDL-C; and
81.8% and 88.9% for LDL-C.
Evaluation of Association of Local Ancestry at Established
Loci with Lipid Traits
For each of the previously validated lipid and cholesterol loci,
we identified the genetic position of the most strongly associated
SNP using NCBI Build 35 of the public genome reference
sequence (http://genome.ucsc.edu) and selected the closest
marker (among equally-spaced markers across the genome, see
above) to estimate the local ancestry at that locus. Local ancestry
was tested for association with lipid phenotypes in a linear
regression model as detailed above.
Online Resources
http://genepath.med.harvard.edu/,reich for our ANCES-
TRYMAP software.
Accession Numbers; Entrez ID for Discussed Genes
APOE – 348; HMGCR – 3156; LDLR – 3949; MVK – 4598;
NCAN; PCSK9 – 255738; SORT1 – 6272; ABCA1 – 19; APOA5
– 116519; CETP – 1071; GALNT2 – 2590; LIPC – 3990; LIPG –
9388; LPL – 4023; MLXIPL – 51085; TRIB1 – 10221;
ANGPTL3 – 27329; APOB 338; GCKR 2646; NCAN – 1463.
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Supporting Information
Figure S1 Average Cases-Only LOD Scores Across the Genome
for a) TG, b) HDL-C, and c) LDL-C. The risk model specified is
for a 1.5-fold increased risk of Case status with inheritance of a
single copy of the i) African or ii) European ancestral allele.
Found at: doi:10.1371/journal.pgen.1000342.s001 (0.55 MB
DOC)
Table S1 Summary of Admixture Scans for Lipid and
Cholesterol Traits. For each trait, 4 scans were performed,
varying the predictors used in the regression model to select cases
and controls, and the method of selecting unrelated individuals.
The genome-wide LOD score and top scores for the Cases only
and Case-Control statistics are shown. The thresholds of a
significant association for the genome-wide and Cases only LOD
scores are 2.0 and 5.0, respectively.
Found at: doi:10.1371/journal.pgen.1000342.s002 (0.04 MB
DOC)
Table S2 Proportion of genome excluded as contributing to
differential risk for triglycerides and cholesterol phenotypes
comparing African and European Americans.
Found at: doi:10.1371/journal.pgen.1000342.s003 (0.03 MB
DOC)
Table S3 Extent of pairwise linkage disequilibrium measured by
r2 for select SNPs in JHS-AFR-2LPL and JHS-EUR-2LPL.
Found at: doi:10.1371/journal.pgen.1000342.s004 (0.13 MB
DOC)
Table S4 Effect size of LPL variants on TG levels. P-values for
association of TRG with genotype in the total population
(p_trg_all) and JHS-AFR-2LPL (p_trg_afr); SNPs with p,0.0006
are shown in bold. The p-value for interaction is for the
significance of the genotype6local ancestry term in the linear
regression model for the total population (p,0.05 is shown in
bold). The percent change in TG level per LPL allele is shown with
standard error (SE) for the total population (effect_all), JHS-AFR-
2LPL (effect_afr) and JHS-EUR-1_2LPL (effect_eur). The SNP
frequencies in the total population (f_all), JHS-AFR-2LPL (f_afr)
and JHS-EUR-2LPL (f_eur) are also shown, as well as the
chromosomal position in bases on chromosome 8.
Found at: doi:10.1371/journal.pgen.1000342.s005 (0.19 MB
DOC)
Table S5 Effect size of LPL variants on HDL-C levels. P-values
for association of HDL-C with genotype in the total population
(p_hdl_all) and for the significance of the genotype6local ancestry
term in the linear regression model. SNPs with p,0.0006 are
shown in bold. The change in HDL-C level (mg/dL) per LPL
allele is shown with standard error for the total population
(effect_all), JHS-AFR-2LPL (effect_afr) and JHS-EUR-1_2LPL
(effect_eur). The SNP frequencies in the total population (f_all),
JHS-AFR-2LPL (f_afr) and JHS-EUR-2LPL (f_eur) are also shown,
as well as the chromosomal position in bases on chromosome 8.
Found at: doi:10.1371/journal.pgen.1000342.s006 (0.18 MB
DOC)
Table S6 Multi-SNP models derived using nested regression
models and ANOVA for a) TG and b) HDL-C. The most frequent
solutions are shown for the 100 runs performed (one run per set of
3300 unrelated individuals).
Found at: doi:10.1371/journal.pgen.1000342.s007 (0.04 MB
DOC)
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